<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01292187</url>
  </required_header>
  <id_info>
    <org_study_id>TAR-01-201</org_study_id>
    <nct_id>NCT01292187</nct_id>
  </id_info>
  <brief_title>A Study of Oral Recombinant Salmon Calcitonin (rsCT) to Prevent Postmenopausal Osteoporosis</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Clinical Trial Evaluating the Safety and Efficacy of Oral Recombinant Salmon Calcitonin (rsCT) in the Prevention of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tarsa Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tarsa Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study was to evaluate the efficacy of oral calcitonin
      (rsCT)tablets in the prevention of bone loss in postmenopausal women with lower bone mineral
      density at increased risk of fracture. The secondary purpose of this study was to determine
      if there is any food effect by comparing the efficacy and safety of oral calcitonin tablets
      administered at dinner or at bedtime.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a randomized, double-blind, placebo-controlled Phase 2 study conducted entirely in
      the US. The subjects were all post-menopausal women whose 10-year risk of major osteoporotic
      fracture was assessed using the World Health Organization (WHO) Fracture Risk Assessment Tool
      (FRAX®) algorithm within the first 3 visits. Eligible, consenting subjects were then enrolled
      and began a 2- week single-blind placebo run-in phase to determine tolerability. After the
      run-in phase, continuing subjects were randomized in a 2:1 ratio to receive oral calcitonin
      or placebo. All subjects took 600 mg calcium citrate and 1000 IU vitamin D once daily with
      breakfast beginning with the run-in phase. The duration of treatment including the run-in
      phase was 54 weeks. Bone mineral density (BMD) and C-terminal telopeptide of type 1 collagen
      (CTx-1) were determined at Baseline and Weeks 28 and 54 after randomization. The % change
      from baseline in lumbar spine BMD was calculated and compared: active to placebo. The change
      from baseline in plasma CTx-1 was also calculated and compared likewise.

      To confirm that there is no effect of meal timing on this product, subjects in both arms were
      further randomized to take the active or placebo on an empty stomach at bedtime or with the
      meal at dinnertime.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Change From Baseline to Week 54 of Lumbar Spine Bone Mineral Density of Active Compared to Placebo.</measure>
    <time_frame>Baseline, Week 54</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline to Week 54 of Plasma CTx-1 Following rsCT Compared to Placebo.</measure>
    <time_frame>Baseline, Week 54</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">129</enrollment>
  <condition>Osteopenia</condition>
  <arm_group>
    <arm_group_label>Oral calcitonin at dinner-or bedtime</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Oral calcitonin at dinnertime or oral calcitonin at bedtime. Postmenopausal subjects with osteopenia were treated for one year (also with vitamin D and calcium supplements) to determine if oral calcitonin tablets would prevent the loss of bone mineral density compared with placebo. Randomization to active or placebo was done 2:1. After randomization, further randomization was done to divide each arm into two groups, one in which dosing was at dinnertime and the other in which dosing was at bedtime to determine if food affected efficacy or safety.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral placebo at dinner- or bedtime</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: oral placebo at dinnertime or oral placebo at bedtime</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral calcitonin at dinnertime</intervention_name>
    <description>Oral calcitonin at dinnertime.</description>
    <arm_group_label>Oral calcitonin at dinner-or bedtime</arm_group_label>
    <other_name>Oral rsCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral placebo at dinnertime</intervention_name>
    <description>Oral placebo at dinnertime.</description>
    <arm_group_label>Oral placebo at dinner- or bedtime</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral calcitonin at bedtime</intervention_name>
    <description>Oral calcitonin at bedtime</description>
    <arm_group_label>Oral calcitonin at dinner-or bedtime</arm_group_label>
    <other_name>Oral rsCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral placebo at bedtime</intervention_name>
    <description>Oral placebo at bedtime</description>
    <arm_group_label>Oral placebo at dinner- or bedtime</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female and at least 45 years of age.

          -  Must have undergone the onset of spontaneous or surgical menopause more than 5 years
             prior to entry. Spontaneous menopause is defined as 12 months of spontaneous
             amenorrhea. Surgical menopause is defined as ≥ 6 weeks postsurgical bilateral
             oophorectomy with or without hysterectomy.

          -  Serum follicle-stimulating hormone (FSH) levels must be ≥ 30 mIU/mL.

          -  A body mass index (BMI) of not greater than 35 (BMI

             =weight [kg]/height[m]2).

          -  Bone mineral density (BMD) T-score between -1.0 and - 2.5 at the total hip, femoral
             neck, trochanter, or lumbar spine.

          -  Additional risk factors such that the 10 year risk of a major osteoporotic fracture or
             hip fracture risk is at least as great as a 65-year-old woman of the same race and BMI
             of 25 kg/m2 as determined by the FRAX algorithm .

          -  No clinically significant abnormal findings in the medical history or physical exam
             that would preclude participation in the investigator's opinion.

          -  No clinically significant abnormal laboratory values at the screening assessment.

          -  Subjects must give written informed consent after reading the Subject Information and
             Consent Form and having had the opportunity to discuss the study with the
             investigator.

        Exclusion Criteria:

          -  History of an osteoporotic fracture, defined as a fracture at the wrist, hip, or
             humerus occurring from a fall at standing height or less.

          -  BMD T-Score at any site ≤ -2.5.

          -  Current treatment (or within 3 months prior to randomization) with hormone replacement
             therapy.

          -  History of metabolic and other bone diseases, including osteogenesis imperfecta,
             osteomalacia, and Paget's disease.

          -  Vitamin D insufficiency defined as a 25 hydroxyvitamin D level &lt; 20 ng/mL (50 nmol/L).

          -  Prior use of calcitonin, ever.

          -  Prior use of any bisphosphonate, ever.

          -  Prior use of denosumab, fluoride, or strontium, ever.

          -  Prior use of parathyroid hormone analogs, ever.

          -  Any condition or disease that may interfere with the ability to have a dual energy
             x-ray absorptiometry (DXA) scan or to evaluate a DXA scan, for example, severe
             osteoarthritis of the spine, spinal fusion, pedicle screws, history of vertebroplasty,
             or degenerative disease that results in insufficient number of evaluable lumbar
             vertebrae, bilateral hip replacements.

          -  Use of anabolic steroids or androgens within 6 months preceding randomization.

          -  Use of vitamin D metabolites and analogs, (e.g., calcitriol) within 3 months preceding
             randomization). Note: Vitamin D supplementation is not exclusionary.

          -  Use of estrogen or estrogen-related drugs (including selective estrogen receptor
             molecules), for example, tamoxifen, tibolone, or raloxifene within 3 months preceding
             randomization.

          -  Chronic systemic treatment with glucocorticoids.

          -  Clinically relevant abnormal history, physical findings, or laboratory values at the
             pre-study screening assessment that could interfere with the objectives of the study
             or the safety of the subject.

          -  Presence of acute or chronic illness or history of chronic illness which, in the
             judgment of the investigator, makes participation in the study medically
             inappropriate.

          -  Known acquired immune deficiency syndrome (AIDS) or human immunodeficiency virus (HIV)
             seropositivity.

          -  Uncontrolled hypertension, significant gastrointestinal abnormalities, uncontrolled
             diabetes mellitus, significant coronary heart disease, any psychotic mental illness,
             chronic allergic rhinitis, asthma, uncorrected endocrine dysfunction, or significantly
             impaired hepatic, respiratory, or renal function.

          -  Participation in any other clinical study within the previous month.

          -  History of drug or alcohol abuse, or intake of more than 30 units of alcohol weekly.

          -  Possibility that the subject will not cooperate with the requirements of the protocol.

          -  Known sensitivity to sCT.

          -  Shift workers-individuals who are at work during overnight hours.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David S. Krause, MD</last_name>
    <role>Study Director</role>
    <affiliation>Chief Medical Officer - Tarsa Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diablo Clinical Research, Inc.</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovative Research of West Florida, Inc.</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bethesda Health Research</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology Study Group</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Bone and Mineral Clinic</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Osteoporosis Center at St. Luke's Hospital</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Clinical Research</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh - Department of Neurology</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Puget Sound Osteoporosis Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.tarsatherapeutics.com</url>
    <description>Related Info.</description>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2011</study_first_submitted>
  <study_first_submitted_qc>February 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2011</study_first_posted>
  <results_first_submitted>July 11, 2013</results_first_submitted>
  <results_first_submitted_qc>September 5, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 12, 2014</results_first_posted>
  <last_update_submitted>September 5, 2014</last_update_submitted>
  <last_update_submitted_qc>September 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoporosis</keyword>
  <keyword>Osteopenia</keyword>
  <keyword>Osteoporosis, Postmenopausal</keyword>
  <keyword>Bone Diseases, Metabolic</keyword>
  <keyword>Bone Diseases</keyword>
  <keyword>Musculoskeletal Diseases</keyword>
  <keyword>Salmon calcitonin</keyword>
  <keyword>Calcitonin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Salmon calcitonin</mesh_term>
    <mesh_term>Calcitonin</mesh_term>
    <mesh_term>Calcitonin Gene-Related Peptide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects will be recruited from outpatient populations associated with health care centers that treat osteoporosis. Community advertising may also be used for those not associated with such centers.
Recruitment began on 17 January 2011.</recruitment_details>
      <pre_assignment_details>All patients had a two-week single-blind oral placebo (at bedtime) run-in period before group assignment. This was to accustom the patients to the oral dose regimen prior to randomization</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Oral rsCT Tablets</title>
          <description>Tablets containing 200 μg of recombinant salmon calcitonin, for oral administration. At group assignment the first 60 patients were told to self-administer the tablets once daily at bedtime (Group 1). The remaining patients were told to self-administer once daily at dinner time (Group 2)to determine if there was any food effect. Randomization was done active:placebo, 2:1.</description>
        </group>
        <group group_id="P2">
          <title>Oral Placebo Tablets</title>
          <description>Identical appearing placebo tablets, without active ingredient At group assignment the first 60 patients were told to self-administer the tablets once daily at bedtime Group 1). The remaining patients enrolled were told to self-administer once daily at dinner time (Group 2)to determine if there was any food effect. Randomization was done active:placebo, 2:1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>All other reasons</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline Lumbar Spine BMD (Bone Mineral Density) T-scores, plasma CTx-1 (collagen type 1 C telopeptide), , FRAX scores, age, race and body weight were compared between the two treatment arms and were found to have similar means, respectively.</population>
      <group_list>
        <group group_id="B1">
          <title>rsCT Tablets</title>
          <description>Patients who received oral calcitonin as an active treatment</description>
        </group>
        <group group_id="B2">
          <title>Placebo Tablets</title>
          <description>Patients who did not receive any active treatment, just placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="86"/>
            <count group_id="B2" value="43"/>
            <count group_id="B3" value="129"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.5" spread="6.90"/>
                    <measurement group_id="B2" value="66.6" spread="5.16"/>
                    <measurement group_id="B3" value="67.2" spread="6.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>T-score</title>
          <description>The National Osteoporosis Foundation suggested that women with osteopenia (T-score between -1.0 and -2.5 Standard Deviations from the BMD mean value of healthy 30-year old women) and additional risk factors should be treated. For entry into this study, the recommendations of the US Preventative Services Task Force (USPSTF) have been adapted, such that subjects with osteopenia (BMD and a 10-year fracture risk at least that of an average risk 65-year-old woman) were included (World Health Organization’s Fracture Risk Assessment Tool (FRAX®) [USPSTF, 2010].</description>
          <units>T-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-1.15" spread="0.881"/>
                    <measurement group_id="B2" value="-1.12" spread="0.864"/>
                    <measurement group_id="B3" value="-1.14" spread="0.872"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FRAX Score</title>
          <description>FRAX® is a computer based algorithm (http://www.shef.ac.uk/FRAX) that provides models for the assessment of fracture probability in men and women. The approach uses easily obtained clinical risk factors to estimate 10 year fracture probability for a major fracture due to osteoporosis. Major fracture means a clinically apparent fracture of the hip, spine, humerus (upper arm) or wrist.</description>
          <units>percent probability</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.87" spread="5.019"/>
                    <measurement group_id="B2" value="11.57" spread="4.468"/>
                    <measurement group_id="B3" value="11.77" spread="4.827"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LS BMD</title>
          <description>LS BMD was determined at baseline with Dual Energy X-ray Absorptionometry (DEXA) scans and expressed as grams/square centimeter. This was used to calculate T-scores and used as the baseline to assess changes.</description>
          <units>grams per square centimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.940" spread="0.106"/>
                    <measurement group_id="B2" value="0.929" spread="0.907"/>
                    <measurement group_id="B3" value="0.936" spread="0.102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.81" spread="3.765"/>
                    <measurement group_id="B2" value="26.77" spread="5.983"/>
                    <measurement group_id="B3" value="26.13" spread="25.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CTx-1</title>
          <description>C-terminal telopeptide-1</description>
          <units>ng/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="423.95" spread="219.419"/>
                    <measurement group_id="B2" value="417" spread="119.882"/>
                    <measurement group_id="B3" value="421.74" spread="193.638"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change From Baseline to Week 54 of Lumbar Spine Bone Mineral Density of Active Compared to Placebo.</title>
        <time_frame>Baseline, Week 54</time_frame>
        <population>MITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Calcitonin Tablets</title>
            <description>Tablets containing 200 μg of recombinant salmon calcitonin, for oral administration. At group assignment the first 60 patients were told to self-administer the tablets once daily at bedtime (Group 1). The remaining patients were told to self-administer once daily at dinner time (Group 2)to determine if there was any food effect. Randomization was done active:placebo, 2:1.</description>
          </group>
          <group group_id="O2">
            <title>Oral Placebo Tablets</title>
            <description>Identical appearing placebo tablets, without active ingredient At group assignment the first 60 patients were told to self-administer the tablets once daily at bedtime Group 1). The remaining patients enrolled were told to self-administer once daily at dinner time (Group 2)to determine if there was any food effect. Randomization was done active:placebo, 2:1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline to Week 54 of Lumbar Spine Bone Mineral Density of Active Compared to Placebo.</title>
          <population>MITT population</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" lower_limit="0.46" upper_limit="1.59"/>
                    <measurement group_id="O2" value="-0.12" lower_limit="-0.94" upper_limit="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0265</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline to Week 54 of Plasma CTx-1 Following rsCT Compared to Placebo.</title>
        <time_frame>Baseline, Week 54</time_frame>
        <population>MITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Oral rsCT Tablets</title>
            <description>Tablets containing 200 μg of recombinant salmon calcitonin, for oral administration. At group assignment the first 60 patients were told to self-administer the tablets once daily at bedtime (Group 1). The remaining patients were told to self-administer once daily at dinner time (Group 2)to determine if there was any food effect. Randomization was done active:placebo, 2:1.</description>
          </group>
          <group group_id="O2">
            <title>Oral Placebo Tablets</title>
            <description>Identical appearing placebo tablets, without active ingredient At group assignment the first 60 patients were told to self-administer the tablets once daily at bedtime Group 1). The remaining patients enrolled were told to self-administer once daily at dinner time (Group 2)to determine if there was any food effect. Randomization was done active:placebo, 2:1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline to Week 54 of Plasma CTx-1 Following rsCT Compared to Placebo.</title>
          <population>MITT population</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.83" lower_limit="-22.43" upper_limit="-1.43"/>
                    <measurement group_id="O2" value="8.37" lower_limit="-7.11" upper_limit="23.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0340</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Oral rsCT Tablets</title>
          <description>Tablets containing 200 μg of recombinant salmon calcitonin, for oral administration. At group assignment the first 60 patients were told to self-administer the tablets once daily at bedtime (Group 1). The remaining patients were told to self-administer once daily at dinner time (Group 2)to determine if there was any food effect. Randomization was done active:placebo, 2:1.</description>
        </group>
        <group group_id="E2">
          <title>Oral Placebo Tablets</title>
          <description>Identical appearing placebo tablets, without active ingredient At group assignment the first 60 patients were told to self-administer the tablets once daily at bedtime Group 1). The remaining patients enrolled were told to self-administer once daily at dinner time (Group 2)to determine if there was any food effect. Randomization was done active:placebo, 2:1.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericardial effusions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <description>Intermittent Fever</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <description>Acute Hepatitis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning and procedural complications</sub_title>
                <description>Laceration/ Cranial Laceration</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified</sub_title>
                <description>Malignant melanoma/ Melanoma On Left Eyelid</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="86"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="86"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="86"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="86"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. David Krause, Chief Medical Officer</name_or_title>
      <organization>Tarsa Therapeutics, Inc.</organization>
      <phone>1-267-273-7940</phone>
      <email>dkrause@tarsatherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

